Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations

Niedbała, Marcin; Malarz, Katarzyna; Sharma, Gitanjali; Kramer‐Marek, Gabriela; Kaspera, Wojciech

doi:10.2147/ott.s215997

Cited by 15 publications

(5 citation statements)

References 177 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obviously, vaccines based on TSA antigens are more selective and effective, but in highly heterogeneous tumors such as GB, it is difficult to find them. The lack of specificity and high expression of epitopes in GB lead to autoimmunity and side effects such as brain inflammation, which limits the tolerability of vaccine-based strategies [ 758 , 759 ]. Nevertheless, here, we discuss the results obtained with the development of cellular (tumor cell and DC) and non-cellular (peptide) vaccines.…”

Section: Immunotherapiesmentioning

confidence: 99%

“…EGFR is also a prevalent molecular target in immunotherapy assays. Rindopepimut (also known as CDX-110) is a small peptide that mimics the mutated region of EGFRvIII and was designed to generate humoral and cytotoxic T cell responses against GB cells expressing this mutation [ 758 ]. The combination of rindopepimut with SOC achieved 24-month OS (phase II, NCT00458601), with 50% of patients developing a humoral immune response to the vaccine.…”

Section: Immunotherapiesmentioning

confidence: 99%

See 1 more Smart Citation

Glioblastoma Therapy: Past, Present and Future

Obrador,

Moreno-Murciano,

Oriol-Caballo

et al. 2024

IJMS

View full text Add to dashboard Cite

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence. The discussion on therapeutic strategies first covers the SOC treatment and targeted therapies that have been shown to interfere with different signaling pathways (pRB/CDK4/RB1/P16ink4, TP53/MDM2/P14arf, PI3k/Akt-PTEN, RAS/RAF/MEK, PARP) involved in GB tumorigenesis, pathophysiology, and treatment resistance acquisition. Below, we analyze several immunotherapeutic approaches (i.e., checkpoint inhibitors, vaccines, CAR-modified NK or T cells, oncolytic virotherapy) that have been used in an attempt to enhance the immune response against GB, and thereby avoid recidivism or increase survival of GB patients. Finally, we present treatment attempts made using nanotherapies (nanometric structures having active anti-GB agents such as antibodies, chemotherapeutic/anti-angiogenic drugs or sensitizers, radionuclides, and molecules that target GB cellular receptors or open the blood–brain barrier) and non-ionizing energies (laser interstitial thermal therapy, high/low intensity focused ultrasounds, photodynamic/sonodynamic therapies and electroporation). The aim of this review is to discuss the advances and limitations of the current therapies and to present novel approaches that are under development or following clinical trials.

show abstract

Section: Immunotherapiesmentioning

confidence: 99%

Section: Immunotherapiesmentioning

confidence: 99%

Glioblastoma Therapy: Past, Present and Future

Obrador,

Moreno-Murciano,

Oriol-Caballo

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Immunotherapy targets tumors directly by engaging the immune system, particularly the acquired immune response. Dendritic cells (DCs), recognized as proficient antigen-presenting cells (APCs), hold a significant position in both innate and adaptive immunity [ 15 ]. DC vaccines are created using mononuclear cells extracted from the patients’ own bodies.…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine

Qian,

Liu,

Zheng

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Neurospagioma, arising from different glial cells such as astrocytes, oligodendrocytes, and ependymal cells, stands as the prevalent intracranial tumor within the central nervous system. Among its variants, glioblastoma (GBM) represents the most aggressive form, characterized by a notably high occurrence rate and a discouragingly low survival prognosis. The formidable challenge posed by glioblastoma underscores its critical importance as a life-threatening ailment. Currently, clinical approaches often involve surgical excision along with a combination of radiotherapy and chemotherapy. However, these treatments frequently result in a notable recurrence rate, accompanied by substantial adverse effects that significantly compromise the overall prognosis. Hence, there is a crucial need to investigate novel and dependable treatment strategies. Dendritic cells (DCs), being specialized antigen-presenting cells (APCs), hold a significant position in both innate and adaptive immune responses. Presently, DC vaccines have gained widespread application in the treatment of various tumors, including neurospoagioma. In this review, we summarize the immunomodulatory effects and related mechanisms of DC vaccines in neurospoagioma as well as the progress of clinical trials to propose possible challenges of DC vaccines and new development directions.

show abstract

“…Dendritic cells (DCs), as the most potent in vivo functional antigen-presenting cells, link innate immunity with adaptive immunity. 6 However, their function is suppressed in gliomas. 7 Therefore, overcoming the dysfunction of DCs in the TME might be critical to treat gliomas.…”

Section: Introductionmentioning

confidence: 99%

“…Dendritic cells (DCs), as the most potent in vivo functional antigen‐presenting cells, link innate immunity with adaptive immunity 6 . However, their function is suppressed in gliomas 7 .…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions

Zhou

Jia

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Introduction Gliomas, especially the glioblastomas, are one of the most aggressive intracranial tumors with poor prognosis. This might be explained by the heterogeneity of tumor cells and the inhibitory immunological microenvironment. Dendritic cells (DCs), as the most potent in vivo functional antigen‐presenting cells, link innate immunity with adaptive immunity. However, their function is suppressed in gliomas. Therefore, overcoming the dysfunction of DCs in the TME might be critical to treat gliomas. Method In this paper we proposed the specificity of the glioma microenvironment, analyzed the pathways leading to the dysfunction of DCs in tumor microenvironment of patients with glioma, summarized influence of DC‐based immunotherapy on the tumor microenvironment and proposed new development directions and possible challenges of DC vaccines. Result DC vaccines can improve the immunosuppressive microenvironment of glioma patients. It will bring good treatment prospects to patients. We also proposed new development directions and possible challenges of DC vaccines, thus providing an integrated understanding of efficacy on DC vaccines for glioma treatment.

show abstract

Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations

Cited by 15 publications

References 177 publications

Glioblastoma Therapy: Past, Present and Future

Glioblastoma Therapy: Past, Present and Future

Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine

Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions

Contact Info

Product

Resources

About